(MD) Mednax - Overview

Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 1.703m USD | Total Return: 42.7% in 12m

Stock Neonatal Care, Maternal Care, Pediatric Care, Hospital Services
Total Rating 60
Risk 69
Buy Signal -0.65
Medical Care Facilities -10.5
Health Care Services +2.5
Market Cap: 1,703m
Avg Trading Vol: 16.8M USD
ATR: 3.51%
Peers RS (IBD): 81.7
Risk 5d forecast
Volatility45.0%
Rel. Tail Risk-11.3%
Reward TTM
Sharpe Ratio0.98
Alpha45.22
Character TTM
Beta0.113
Beta Downside0.365
Drawdowns 3y
Max DD54.81%
CAGR/Max DD0.24
EPS (Earnings per Share) EPS (Earnings per Share) of MD over the last years for every Quarter: "2021-03": 0.24, "2021-06": 0.41, "2021-09": 0.46, "2021-12": 0.52, "2022-03": 0.33, "2022-06": 0.47, "2022-09": 0.4, "2022-12": 0.47, "2023-03": 0.23, "2023-06": 0.39, "2023-09": 0.32, "2023-12": 0.32, "2024-03": 0.2, "2024-06": 0.34, "2024-09": 0.44, "2024-12": 0.51, "2025-03": 0.2427, "2025-06": 0.53, "2025-09": 0.67, "2025-12": 0.5, "2026-03": 0,
EPS CAGR: -49.43%
EPS Trend: -3.9%
Last SUE: -3.39
Qual. Beats: 0
Revenue Revenue of MD over the last years for every Quarter: 2021-03: 446.753, 2021-06: 472.959, 2021-09: 492.949, 2021-12: 498.53, 2022-03: 482.229, 2022-06: 486.033, 2022-09: 489.915, 2022-12: 513.844, 2023-03: 491.008, 2023-06: 500.577, 2023-09: 506.612, 2023-12: 496.443, 2024-03: 495.101, 2024-06: 504.296, 2024-09: 511.158, 2024-12: 502.364, 2025-03: 458.359, 2025-06: 468.844, 2025-09: 492.875, 2025-12: 493.771, 2026-03: null,
Rev. CAGR: 0.63%
Rev. Trend: -17.0%
Last SUE: 0.53
Qual. Beats: 0
Description: MD Mednax

Pediatrix Medical Group, Inc. (MD) delivers specialized healthcare services for newborns, mothers, and children across the United States. The companys core business involves providing neonatal and maternal-fetal care within hospital settings, primarily Neonatal Intensive Care Units (NICUs).

MDs business model relies on a network of affiliated subspecialists and clinicians to offer inpatient and office-based care. This includes services for premature or complicated births, as well as care for expectant mothers and unborn babies. The healthcare services sector often involves complex billing and regulatory environments.

The company also extends its services to other pediatric subspecialties and provides support within various hospital departments. Outsourcing specialized medical services to dedicated groups like Pediatrix is a common practice in hospitals to optimize resource allocation and expertise.

For more detailed financial and operational insights, consider exploring ValueRays comprehensive analysis.

Headlines to Watch Out For
  • NICU patient volume directly impacts revenue
  • Maternal-fetal medicine growth expands service offerings
  • Physician and clinician labor costs affect profitability
  • Regulatory changes in healthcare reimbursement pose risk
  • Birth rate fluctuations influence demand for services
Piotroski VR‑10 (Strict) 7.5
Net Income: 165.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA 2.67 > 1.0
NWC/Revenue: 15.92% < 20% (prev 10.21%; Δ 5.71% < -1%)
CFO/TA 0.12 > 3% & CFO 271.1m > Net Income 165.4m
Net Debt (285.1m) to EBITDA (268.3m): 1.06 < 3
Current Ratio: 1.66 > 1.5 & < 3
Outstanding Shares: last quarter (84.4m) vs 12m ago -1.69% < -2%
Gross Margin: 25.50% > 18% (prev 0.23%; Δ 2.53k% > 0.5%)
Asset Turnover: 87.01% > 50% (prev 93.51%; Δ -6.50% > 0%)
Interest Coverage Ratio: 8.19 > 6 (EBITDA TTM 268.3m / Interest Expense TTM 30.1m)
Altman Z'' 1.46
A: 0.14 (Total Current Assets 763.5m - Total Current Liabilities 458.9m) / Total Assets 2.25b
B: -0.04 (Retained Earnings -83.2m / Total Assets 2.25b)
C: 0.11 (EBIT TTM 246.5m / Avg Total Assets 2.20b)
D: -0.06 (Book Value of Equity -81.7m / Total Liabilities 1.38b)
Altman-Z'' Score: 1.46 = BB
Beneish M -3.30
DSRI: 0.93 (Receivables 242.3m/272.6m, Revenue 1.91b/2.01b)
GMI: 0.89 (GM 25.50% / 22.57%)
AQI: 0.94 (AQ_t 0.63 / AQ_t-1 0.67)
SGI: 0.95 (Revenue 1.91b / 2.01b)
TATA: -0.05 (NI 165.4m - CFO 271.1m) / TA 2.25b)
Beneish M-Score: -3.30 (Cap -4..+1) = AA
What is the price of MD shares? As of April 03, 2026, the stock is trading at USD 21.39 with a total of 878,349 shares traded.
Over the past week, the price has changed by -2.31%, over one month by +5.77%, over three months by -2.77% and over the past year by +42.66%.
Is MD a buy, sell or hold? Mednax has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold MD.
  • StrongBuy: 3
  • Buy: 0
  • Hold: 5
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the MD price?
Wallstreet Target Price 21.3 -0.3%
Analysts Target Price 21.3 -0.3%
MD Fundamental Data Overview as of 29 March 2026
P/E Trailing = 10.567
P/E Forward = 8.2102
P/S = 0.8898
P/B = 2.0112
P/EG = 0.2433
Revenue TTM = 1.91b USD
EBIT TTM = 246.5m USD
EBITDA TTM = 268.3m USD
Long Term Debt = 570.5m USD (from longTermDebt, last quarter)
Short Term Debt = 38.4m USD (from shortTermDebt, last quarter)
Debt = 660.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 285.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.99b USD (1.70b + Debt 660.3m - CCE 375.2m)
Interest Coverage Ratio = 8.19 (Ebit TTM 246.5m / Interest Expense TTM 30.1m)
EV/FCF = 7.87x (Enterprise Value 1.99b / FCF TTM 252.6m)
FCF Yield = 12.71% (FCF TTM 252.6m / Enterprise Value 1.99b)
FCF Margin = 13.20% (FCF TTM 252.6m / Revenue TTM 1.91b)
Net Margin = 8.64% (Net Income TTM 165.4m / Revenue TTM 1.91b)
Gross Margin = 25.50% ((Revenue TTM 1.91b - Cost of Revenue TTM 1.43b) / Revenue TTM)
Gross Margin QoQ = 24.37% (prev 28.48%)
Tobins Q-Ratio = 0.88 (Enterprise Value 1.99b / Total Assets 2.25b)
Interest Expense / Debt = 1.32% (Interest Expense 8.74m / Debt 660.3m)
Taxrate = 26.13% (11.9m / 45.6m)
NOPAT = 182.1m (EBIT 246.5m * (1 - 26.13%))
Current Ratio = 1.66 (Total Current Assets 763.5m / Total Current Liabilities 458.9m)
Debt / Equity = 0.76 (Debt 660.3m / totalStockholderEquity, last quarter 865.9m)
Debt / EBITDA = 1.06 (Net Debt 285.1m / EBITDA 268.3m)
Debt / FCF = 1.13 (Net Debt 285.1m / FCF TTM 252.6m)
Total Stockholder Equity = 844.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.52% (Net Income 165.4m / Total Assets 2.25b)
RoE = 19.58% (Net Income TTM 165.4m / Total Stockholder Equity 844.9m)
RoCE = 17.42% (EBIT 246.5m / Capital Employed (Equity 844.9m + L.T.Debt 570.5m))
RoIC = 12.57% (NOPAT 182.1m / Invested Capital 1.45b)
WACC = 4.87% (E(1.70b)/V(2.36b) * Re(6.38%) + D(660.3m)/V(2.36b) * Rd(1.32%) * (1-Tc(0.26)))
Discount Rate = 6.38% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 33.33 | Cagr: 0.24%
[DCF] Terminal Value 88.44% ; FCFF base≈225.4m ; Y1≈278.1m ; Y5≈474.4m
[DCF] Fair Price = 162.2 (EV 13.76b - Net Debt 285.1m = Equity 13.48b / Shares 83.1m; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -3.87 | EPS CAGR: -49.43% | SUE: -3.39 | # QB: 0
Revenue Correlation: -17.04 | Revenue CAGR: 0.63% | SUE: 0.53 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.59 | Chg7d=+0.024 | Chg30d=+0.024 | Revisions Net=+3 | Analysts=7
EPS current Year (2026-12-31): EPS=2.23 | Chg7d=+0.048 | Chg30d=+0.048 | Revisions Net=+3 | Growth EPS=+9.5% | Growth Revenue=+0.7%
EPS next Year (2027-12-31): EPS=2.33 | Chg7d=+0.025 | Chg30d=+0.025 | Revisions Net=+1 | Growth EPS=+4.1% | Growth Revenue=+2.6%
[Analyst] Revisions Ratio: +1.00 (3 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -1.5% (Discount Rate 7.9% - Earnings Yield 9.5%)
[Growth] Growth Spread = +2.9% (Analyst 1.3% - Implied -1.5%)
External Resources
Dataroma Stockcircle